ReviewMolecular biology reports2026
Stage-dependent signaling networks and therapeutic strategies in diabetic retinopathy: from neurovascular dysfunction to angiogenesis and fibrosis.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Diabetic retinopathy (DR) is a consequence of multiple metabolic, neuronal, inflammatory, vascular and fibrotic changes, not a single cause. Early hyperglycaemia, oxidative stress, lipid disturbance, and mitochondrial dysfunction weaken the retinal neurovascular unit before clinically apparent vascular changes develop. With the accumulation of damage, nuclear factor kappa B, high-mobility group box 1, Toll-like receptor 4, receptor for advanced glycation end products, cyclic GMP-AMP synthase-stimulator of interferon genes, and the NOD-like receptor protein 3 inflammasome enhance inflammation, leukostasis and blood-retinal barrier dysfunction. Capillary loss then promotes hypoxia-inducible factor 1 alpha and vascular endothelial growth factor signalling, and angiopoietin-2, Wnt/beta-catenin, phosphoinositide 3-kinase/protein kinase B, semaphorin 4D, and endothelial metabolic reprogramming sustain leakage and neovascularisation. In advanced disease, Transforming Growth Factor Beta, Yes-associated Protein/transcriptional coactivator with PDZ-binding motif and related pathways drive extracellular matrix deposition, fibrovascular membrane formation and traction. Organise the mechanisms in this review according to disease stage and retinal cell type, and highlight pathway crosstalk, feedback loops, and altered biological functions during progression. Distinguish between clinical data and non-clinical studies, and conduct studies at all stages. Systemic metabolic control and fenofibrate have shown the most promise for early-stage disease, and anti-vascular endothelial growth factor therapy is still used in severe vascular complications. Anti-inflammatory, neuroprotective, anti-fibrotic, gene-based and multi-target approaches are promising but still have limitations in delivery, safety, model-to-human translation and weak biomarker validation. Improve the classification of molecules and find clinically significant early endpoints for targeted therapy.
Indexed as
Identifiers
42886381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.